Drug Eluting Stents
5.2K views | +10 today
Follow
Drug Eluting Stents
Your new post is loading...
Your new post is loading...
Scooped by Beeyond
Scoop.it!

Drug-Eluting Stents Risky Without Blood Thinner,

Drug-Eluting Stents Risky Without Blood Thinner, | Drug Eluting Stents | Scoop.it
Heart patients with drug-eluting stents implanted to keep their arteries open were found to have a much higher risk of sudden death than those getting bare metal stents if they stopped taking the blood thinner Plavix, a new Swiss study reports.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Impact of Diabetes on Short- vs Long-Term DAPT Following Drug-Eluting Stent Implantation

Impact of Diabetes on Short- vs Long-Term DAPT Following Drug-Eluting Stent Implantation | Drug Eluting Stents | Scoop.it
Although diabetes is a risk factor for cardiovascular events following PCI with drug-eluting stents, long-term DAPT did not reduce MACE but did increase bleeding risk. The authors propose that short-term treatment is as effective and may reduce the risks and costs associated with prolonged treatment. They suggest that diabetes itself should not be a basis for prolonging antiplatelet treatment following drug-eluting stent implantation.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

When is the vascular healing complete after the drug eluting stent implantation?

When is the vascular healing complete after the drug eluting stent implantation? | Drug Eluting Stents | Scoop.it
On the 1st generation DES, the struts without endothelial coverage are frequently observed at follow-up by optical coherence tomography (OCT) which is an intracoronary imaging modality with high resolution of approximately 10-20 μm. 2nd generation DES are more biocompatible than 1st generation DES. It improved the vascular healing and decreased inflammatory response compared with the 1st generation DES. Previous study showed that 2nd generation DES, everolimus-eluting stent (EES) had a higher rate of endothelial coverage than 1st generation DES evaluated by OCT.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

OrbusNeich Introduces a New Generation COMBO Plus Dual Therapy Stent for Active Healing

OrbusNeich Introduces a New Generation COMBO Plus Dual Therapy Stent for Active Healing | Drug Eluting Stents | Scoop.it
Multiple design features make COMBO Plus a unique and effective option for treating coronary stenosis. Following implantation, the biological coating on the outer surface of the COMBO Plus immediately captures endothelial progenitor cells and initiates the formation of an endothelial layer. This accelerated healing process, leads to earlier return of functionality and may reduce adverse events in the long-term. In concert with the biological layer, a directional coating of bioabsorbable polymer elutes sirolimus to inhibit neointimal hyperplasia.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Domestic stent maker SMT fights perception with new trial

Domestic stent maker SMT fights perception with new trial | Drug Eluting Stents | Scoop.it
Mumbai-based Sahajanand Medical Technologies (SMT), India’s largest manufacturer of cardiovascular stents, has begun clinical trials in Europe so that it can compete with global rivals Abbott and Medtronic.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Trump’s Unexpected Win Met With Everything From Shock to Optimism Among US Cardiologists

Trump’s Unexpected Win Met With Everything From Shock to Optimism Among US Cardiologists | Drug Eluting Stents | Scoop.it
The idea that the 2.3% medical device tax—enacted as part of the ACA—will be axed during a Trump presidency is also seen as a strong possibility by AdvaMed, a trade association for the medical device industry. In a statement sent to TCTMD, CEO Scott Whitaker said that in the next year, “policymakers will be dealing with a number of important policy issues, including authorization of the latest Medical Device User Fee agreement to continue improving the FDA regulatory process, repeal of the medical device tax, and ensuring that the coverage process allows patient access to the latest innovations. These have been and will always be bipartisan issues.”
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

In-Stent Atherosclerosis at a Crossroads

In-Stent Atherosclerosis at a Crossroads | Drug Eluting Stents | Scoop.it
Although in-stent atherosclerosis has recently been the subject of continued concern and investigation, the mechanisms of its development remain unknown. The prevailing hypothesis is that it occurs due to the formation of de novo atherosclerosis within the neointima, which has led to the widespread adoption of the term “neoatherosclerosis.” However, the underlying native atherosclerotic plaque might as well contribute to the pathogenesis of this disease entity, a hypothesis largely overlooked in recent reports.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

New treatment strategy effective in preventing bleeding in AF patients who underwent PCI, study shows

New treatment strategy effective in preventing bleeding in AF patients who underwent PCI, study shows | Drug Eluting Stents | Scoop.it
A new study led by clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) testing the safety and effectiveness of anticoagulant strategies for patients with atrial fibrillation who undergo stenting procedures has shown that therapies combining the anticoagulant drug rivaroxaban with either single or dual anti-platelet therapy (DAPT) were more effective in preventing bleeding complications than the current standard of care.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Study Suggests Heart-Disease Patients May Need Fewer Blood Thinners

Study Suggests Heart-Disease Patients May Need Fewer Blood Thinners | Drug Eluting Stents | Scoop.it
NEW ORLEANS—Researchers said a study involving reduced doses of Johnson & Johnson’s anticoagulant Xarelto suggests it may be possible for patients with two types of heart disease to avoid the need for three different blood thinners to protect them from stroke and heart attack.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

First in human of new polymer-free stent demonstrates favorable angiographic, imaging-based outcomes at nine-months

First in human of new polymer-free stent demonstrates favorable angiographic, imaging-based outcomes at nine-months | Drug Eluting Stents | Scoop.it
A first-in-human study of a new polymer-free drug-filled stent, which provides controlled drug elution from an internal lumen, indicated non-inferior in-stent late lumen loss at nine-months compared with historical zotarolimus-eluting stent (Resolute) data.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

MicroPort Scientific Corporation - Financial and Strategic SWOT Analysis Review

MicroPort Scientific Corporation - Financial and Strategic SWOT Analysis Review | Drug Eluting Stents | Scoop.it
MicroPort Scientific Corporation (MicroPort) a subsidiary of Otsuka Medical Devices Co., Ltd. is a medical device company that develops, manufactures and markets cardiovascular treatment devices. The company offers products such as cardiovascular devices, orthopedic devices, endovascular devices, electrophysiological devices, neurovascular devices, diabetes care and endocrinal; and surgical management products. It also provides products for coronary drug eluting stents, artificial joints, aortic stents, cerebral vascular stents and electrophysiology equipment.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Novel Dimension to the Assessment of New-Generation Drug-Eluting Stents

Novel Dimension to the Assessment of New-Generation Drug-Eluting Stents | Drug Eluting Stents | Scoop.it
Bioresorbable polymer-based drug-eluting stents (BP-EES) are comparable to durable polymer-based drug-eluting stents (DP-ZES), suggested the results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OCT) to evaluate strut coverage and neoatherosclerosis (NA).
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix. Part 1 of 3

The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix. Part 1 of 3 | Drug Eluting Stents | Scoop.it
The Problem Of Treating Patients With Heart Disease Who Do Not Respond To Plavix. Higher doses of the blood-thinner Plavix were no better at preventing essence attacks, blood clots or extirpation than the standard lower dose in patients who had received artery-opening stents, new research shows. The higher dose – double-dealing the usual amount – was tested in patients with “high platelet reactivity,” meaning they failed to respond to the drug at lower doses. Plavix (clopidogrel) helps prevent clots from forming in patients who have glum platelet reactivity and who have had stents inserted to prop open blocked arteries.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Smart skin patch releases blood thinners in closed-loop control system

Smart skin patch releases blood thinners in closed-loop control system | Drug Eluting Stents | Scoop.it

North Carolina researchers have developed a smart skin patch designed to monitor a patient’s blood and release a blood-thinning drug, as needed, to prevent thrombosis (dangerous blood clots).
Thrombosis — one of the leading causes of cardiovascular mortalities and morbidities worldwide — occurs when blood clots disrupt the normal flow of blood in the body, which can cause severe health problems such as pulmonary embolism, heart attack, or stroke.

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

How Angiogram & Angioplasty is Done? Simple Animation Video For Education

How Angiogram & Angioplasty is Done? Simple Animation Video For Education Angigram and angioplasty are not curable heart problems in old days,now it ha
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Evaluation of a Bioabsorbable Self-Expandable Vein Stent-Base Made of Poly(l-lactide) In Vitro and In Vivo

Evaluation of a Bioabsorbable Self-Expandable Vein Stent-Base Made of Poly(l-lactide) In Vitro and In Vivo | Drug Eluting Stents | Scoop.it
A bioabsorbable self-expandable stent-base made from PLLA for large veins seems feasible, but over time, the PLLA used in this study appears too stiff and lacks the sufficient flexibility to move with the vena cava, causing multiple fractures.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Global Coronary Stents Market will be worth USD 6.1 billion by 2022

Global Coronary Stents Market will be worth USD 6.1 billion by 2022 | Drug Eluting Stents | Scoop.it
On the basis of type, the global coronary stents market is segmented into dual therapy stent, bioresorbable vascular scaffold (BVS), drug eluting stent (DES), bio-engineered stent, bare metal stent. The drug eluting stent market is segmented into biodegradable and non-biodegradable.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Indian's Red Tape Delays Stent Price Fixing

Indian's Red Tape Delays Stent Price Fixing | Drug Eluting Stents | Scoop.it
The Department of Pharmaceuticals has been sitting on the health ministry’s recommendations for over 90 days and in the absence of a pharmaceutical department order, the National Pharmaceutical Pricing Authority (NPPA) could not start the price fixation process to include this medical device in the National List of Essential Medicine (NLEM), sources told DH.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

OrbusNeich launches new Dual Therapy Stent for active vessel healing

OrbusNeich launches new Dual Therapy Stent for active vessel healing | Drug Eluting Stents | Scoop.it
OrbusNeich has announced the launch of its latest generation Dual Therapy Stent (DTS), the COMBO Plus. The COMBO Plus has a unique anti-CD34 antibody biological coating that offers an advanced approach to active vessel healing combined with improved deliverability for patients with complex coronary artery disease.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Admedes Case Study: Simulating Smarter Stents

Admedes Case Study: Simulating Smarter Stents | Drug Eluting Stents | Scoop.it
This is the work of Admedes Schuessler GmbH, a global manufacturer of stents and other lifesaving devices. Since 1996 Admedes has specialized in laser micromachining, assembly, and finishing of self-expanding Nitinol components for the medical industry. The teams in Germany and the United States consult with customers on product design and material selection, and offer services such as laboratory testing, prototype development, and full scale production of Nitinol-based medical products. They use Abaqus FEA software from Dassault Systèmes SIMULIA both internally and for their customers.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes

Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes | Drug Eluting Stents | Scoop.it
Although the presence of diabetes emerged as an independent predictor of MACE after implantation of a drug eluting stent, compared with short term DAPT, long term DAPT did not reduce the risk of MACE but increased the risk of bleeding among patients with stents with and without diabetes.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Cardiac Stents and Bypass Surgery Are Equally Safe and Effective

Cardiac Stents and Bypass Surgery Are Equally Safe and Effective | Drug Eluting Stents | Scoop.it
Drug-eluting stents are as effective as coronary-artery bypass grafting (CABG) surgery for many patients with left main coronary artery disease (LMCAD), according to a new study.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Stents + Sensibility: Talking Technology + Trends with Cardiology Device Makers

Stents + Sensibility: Talking Technology + Trends with Cardiology Device Makers | Drug Eluting Stents | Scoop.it
Cardiovascular Business invited the chief medical officers of three stent companies to discuss the usage of new and old technologies; why they may diversify their product lines to include healthcare services, such as cardiac catheterization laboratory management; and predictions for the future.
Beeyond's insight:

The stent business continues to see trends exclusively among technologies, while the rest of healthcare struggles with outcome optimization... The wake up call promises to be tough...

more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Bypass Beats Stents for Diabetic Heart Patients

Bypass Beats Stents for Diabetic Heart Patients | Drug Eluting Stents | Scoop.it
The study adds more evidence that bypass is the preferred approach for this type of patient, according to experts discussing the findings Sunday at the annual meeting of the American Heart Association in Los Angeles.
more...
No comment yet.
Scooped by Beeyond
Scoop.it!

Long- vs. Short-Term Dual Antiplatelet Therapy in Diabetes: Little Benefit, Increased Bleeding

Long- vs. Short-Term Dual Antiplatelet Therapy in Diabetes: Little Benefit, Increased Bleeding | Drug Eluting Stents | Scoop.it
In patients with diabetes who've received a drug-eluting stent, long-term dual antiplatelet therapy (DAPT) confers higher bleeding risks than short-term therapy, with no apparent benefit to cardiovascular outcomes, a BMJ meta-analysis finds.
more...
No comment yet.